Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients. [electronic resource]
Producer: 20120611Description: 819-27 p. digitalISSN:- 1573-0646
- Adult
- Aged
- Antineoplastic Agents -- therapeutic use
- Asian People -- genetics
- Benzamides
- Chi-Square Distribution
- DNA Mutational Analysis
- Disease Progression
- Disease-Free Survival
- Exons
- Female
- Gastrointestinal Stromal Tumors -- drug therapy
- Genetic Predisposition to Disease
- Humans
- Imatinib Mesylate
- Indoles -- adverse effects
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Molecular Targeted Therapy
- Multivariate Analysis
- Mutation
- Phenotype
- Piperazines -- adverse effects
- Protein Kinase Inhibitors -- adverse effects
- Proto-Oncogene Proteins c-kit -- antagonists & inhibitors
- Pyrimidines -- adverse effects
- Pyrroles -- adverse effects
- Receptor, Platelet-Derived Growth Factor alpha -- antagonists & inhibitors
- Republic of Korea -- epidemiology
- Retrospective Studies
- Risk Assessment
- Risk Factors
- Sunitinib
- Time Factors
- Treatment Failure
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.